{
    "clinical_study": {
        "@rank": "119352", 
        "arm_group": [
            {
                "arm_group_label": "Cognitive Behavioral Therapy Condition", 
                "arm_group_type": "Experimental", 
                "description": "This arm is the experimental condition; it consists of 12 weekly CBT sessions. The therapy protocol will begin with an introductory education session which will include development of a fear hierarchy, followed by 11 sessions of in vivo exposures to feared triggers."
            }, 
            {
                "arm_group_label": "Treatment as Usual", 
                "arm_group_type": "Active Comparator", 
                "description": "This arm acts as the comparison condition. Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment."
            }
        ], 
        "brief_summary": {
            "textblock": "Autism spectrum disorders affect as many as 1 out of 88 children and are related to\n      significant impairment in social, adaptive, and school functioning. Co-occurring conditions,\n      such as anxiety, are common and may cause substantial distress and impairment beyond that\n      caused by the autism diagnosis. Accordingly, we are proposing a randomized controlled trial\n      to examine the effectiveness of a form of cognitive-behavioral therapy relative to treatment\n      as usual (TAU) in 50 youth ages 6-12 with autism spectrum disorders and comorbid anxiety."
        }, 
        "brief_title": "Exposure-Focused Family-Based CBT for Youth With ASD and Comorbid Anxiety", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Autism", 
            "Asperger's Syndrome", 
            "Pervasive Developmental Disorder Not Otherwise Specified", 
            "Generalized Anxiety Disorder", 
            "Social Phobia", 
            "Separation Anxiety Disorder", 
            "Obsessive-compulsive Disorder", 
            "Specific Phobia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anxiety Disorders", 
                "Anxiety, Separation", 
                "Mental Disorders", 
                "Autistic Disorder", 
                "Developmental Disabilities", 
                "Obsessive-Compulsive Disorder", 
                "Phobic Disorders", 
                "Asperger Syndrome", 
                "Child Development Disorders, Pervasive", 
                "Compulsive Personality Disorder"
            ]
        }, 
        "detailed_description": {
            "textblock": "Autism spectrum disorders affect as many as 1 out of 88 children and are related to\n      significant impairment in social, adaptive, and school functioning. Co-occurring conditions,\n      such as anxiety, are common and may cause substantial distress and impairment beyond that\n      caused by the autism diagnosis. Many children with anxiety disorders, especially those on\n      the autism spectrum, do not receive evidence based treatment, which has fueled the\n      development and evaluation of cognitive-behavioral therapy (CBT). Accordingly, we are\n      proposing a randomized controlled trial to examine the efficacy of exposure based CBT that\n      heavily incorporates parents (EF-CBT) relative to a TAU condition (TAU) in 50 youth ages\n      6-12 years with ASD and comorbid anxiety disorder(s)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Outpatient children with an autism spectrum disorder between the ages 6-12 years.\n\n          -  Meets criteria for a diagnosis of one of the following anxiety disorders: generalized\n             anxiety disorder, separation anxiety disorder, social phobia, specific phobia, panic\n             disorder or obsessive-compulsive disorder.\n\n          -  Minimum score of 12 on the Pediatric Anxiety Rating Scale - Severity Scale.\n\n          -  Child has a Full Scale and Verbal Comprehension IQ > 80.\n\n        Exclusion Criteria:\n\n          -  Current clinically significant suicidality or engagement in suicidal behaviors within\n             the last 6 months.\n\n          -  Presence of any clinical features requiring a higher level of care (inpatient or\n             partial hospital treatment).\n\n          -  Any lifetime diagnosis (meeting DSM-IV criteria) of bipolar disorder, schizophrenia\n             or schizoaffective disorder; or Substance abuse in the past 6 months.\n\n          -  Initiation of an antidepressant medication within 10 weeks before study enrollment or\n             an antipsychotic medication 6 weeks before study enrollment or the child has changed\n             the dose of an established medication within 6 weeks before study enrollment (4 weeks\n             for antipsychotic) or during psychotherapy (unless the dose is lowered because of\n             side effects). If the child is on a medication, she or he can remain on it at its\n             current dose. While in their treatment arm, children randomized to the EF-CBT\n             condition will not be able to continue or initiate psychosocial interventions\n             targeting anxiety(psychotherapy, certain types of social skills training, applied\n             behavior analysis targeting anxiety). Those in the TAU arm will be able to seek out\n             psychiatric/psychological services at their discretion."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "12 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01919970", 
            "org_study_id": "ASD-FET 2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cognitive Behavioral Therapy Condition", 
                "description": "This condition involves 12 weekly CBT sessions.", 
                "intervention_name": "Cognitive Behavioral Therapy", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Treatment as Usual", 
                "description": "This condition allows participants to seek out various services. Considering the number of possible treatment options, there is no way to identify or list them.", 
                "intervention_name": "Treatment as usual", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Autism", 
            "Asperger's Syndrome", 
            "Pervasive Developmental Disorder Not Otherwise Specified", 
            "Treatment", 
            "Cognitive-behavioral therapy", 
            "Anxiety", 
            "Children", 
            "Therapy", 
            "Generalized Anxiety Disorder", 
            "Social Phobia", 
            "Separation Anxiety Disorder", 
            "Obsessive-compulsive Disorder", 
            "Specific Phobia"
        ], 
        "lastchanged_date": "January 2, 2014", 
        "location": {
            "contact": {
                "email": "estorch@health.usf.edu", 
                "last_name": "Eric Storch, Ph.D.", 
                "phone": "727-767-8230"
            }, 
            "contact_backup": {
                "email": "acollie2@health.usf.edu", 
                "last_name": "Amanda Collier, B.A.", 
                "phone": "727 767 7376"
            }, 
            "facility": {
                "address": {
                    "city": "St. Petersburg", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33701"
                }, 
                "name": "Rothman Center for Neuropsychiatry"
            }, 
            "investigator": [
                {
                    "last_name": "Adam Lewin, Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Tanya Murphy, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Exposure-Focused Family-Based CBT for Youth With ASD and Comorbid Anxiety", 
        "overall_contact": {
            "email": "estorch@health.usf.edu", 
            "last_name": "Eric Storch, Ph.D.", 
            "phone": "727 767 8230"
        }, 
        "overall_contact_backup": {
            "email": "acollie2@health.usf.edu", 
            "last_name": "Amanda Collier, B.A.", 
            "phone": "727 767 7376"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Pediatric Anxiety Rating Scale", 
            "safety_issue": "No", 
            "time_frame": "After an average of 12 weeks (post-treatment)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01919970"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Clinical Global Impression - Severity Scale", 
            "safety_issue": "No", 
            "time_frame": "After an average of 12 weeks (Post-treatment)"
        }, 
        "source": "University of South Florida", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of South Florida", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}